Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 11:42:54 UTC 2023
by
admin
on
Sat Dec 16 11:42:54 UTC 2023
|
| Protein Type | RECEPTOR |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
XC55JSP2CX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
P25021
Created by
admin on Sat Dec 16 11:42:56 UTC 2023 , Edited by admin on Sat Dec 16 11:42:56 UTC 2023
|
PRIMARY | |||
|
P25021
Created by
admin on Sat Dec 16 11:42:56 UTC 2023 , Edited by admin on Sat Dec 16 11:42:56 UTC 2023
|
PRIMARY | |||
|
XC55JSP2CX
Created by
admin on Sat Dec 16 11:42:56 UTC 2023 , Edited by admin on Sat Dec 16 11:42:56 UTC 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_91 | 1_174 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_4 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INVERSE AGONIST->TARGET | |||
|
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INVERSE AGONIST->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
BINDING
IC50
|
||
|
WEAK INHIBITOR->TARGET |
IC50
|
||
|
|
INHIBITOR -> TRANSPORTER | |||
|
WEAK INHIBITOR->TARGET |
INHIBITOR
Ki
|
||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
RADIOLIGAND->TARGET |
Kd
|
||
|
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
WEAK INHIBITOR->TARGET |
INHIBITOR
Ki
|
||
|
INHIBITOR->OFF-TARGET |
Radioligand binding assay
BINDING
IC50
|
||
|
INVERSE AGONIST->TARGET |
The mean minimum daily requirement of famotidine to control gastric acid hypersecretion was 0.24 g (range 0.08–0.48 g) compared with 2.1 g (range 0.6–3.6 g) for ranitidine and 7.8 g (range 1.2–13.2 g) for cimetidine. is nine times more potent than ranitidine and 32 times more potent than cimetidine, has a longer duration of action than ranitidine or cimetidine,
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT | CHEMICAL |
|